MX2022006188A - Variantes del vector viral adenoasociado. - Google Patents

Variantes del vector viral adenoasociado.

Info

Publication number
MX2022006188A
MX2022006188A MX2022006188A MX2022006188A MX2022006188A MX 2022006188 A MX2022006188 A MX 2022006188A MX 2022006188 A MX2022006188 A MX 2022006188A MX 2022006188 A MX2022006188 A MX 2022006188A MX 2022006188 A MX2022006188 A MX 2022006188A
Authority
MX
Mexico
Prior art keywords
viral vector
adeno
associated viral
vector variants
targeting peptides
Prior art date
Application number
MX2022006188A
Other languages
English (en)
Inventor
Beverly Davidson
Yonghong Chen
Paul T Ranum
Xueyuan Liu
Original Assignee
Childrens Hospital Philadelphia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Hospital Philadelphia filed Critical Childrens Hospital Philadelphia
Publication of MX2022006188A publication Critical patent/MX2022006188A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14145—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14171—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

En la presente se proveen péptidos dirigidos y vectores que contienen una secuencia que codifica los péptidos dirigidos que administran agentes a subestructuras específicas en el cerebro; en la presente se proveen vectores virales que comprenden cada uno un cápside modificado, en donde el cápside modificado comprende al menos una secuencia de aminoácidos que dirige el vector viral a una estructura cerebral distinta.
MX2022006188A 2019-11-22 2020-11-20 Variantes del vector viral adenoasociado. MX2022006188A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962939315P 2019-11-22 2019-11-22
US202063084709P 2020-09-29 2020-09-29
PCT/US2020/061464 WO2021102234A1 (en) 2019-11-22 2020-11-20 Adeno-associated viral vector variants

Publications (1)

Publication Number Publication Date
MX2022006188A true MX2022006188A (es) 2022-08-22

Family

ID=75980202

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022006188A MX2022006188A (es) 2019-11-22 2020-11-20 Variantes del vector viral adenoasociado.

Country Status (12)

Country Link
US (2) US20230346981A1 (es)
EP (1) EP4061427A4 (es)
JP (1) JP2023503455A (es)
KR (1) KR20220116459A (es)
CN (1) CN115023242A (es)
AU (1) AU2020388404A1 (es)
BR (1) BR112022009864A2 (es)
CA (1) CA3159113A1 (es)
CO (1) CO2022008507A2 (es)
IL (1) IL293140A (es)
MX (1) MX2022006188A (es)
WO (1) WO2021102234A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023205397A1 (en) * 2022-04-22 2023-10-26 The Children's Hospital Of Philadelphia Human ependyma-specific promoter and uses thereof
WO2023220287A1 (en) * 2022-05-11 2023-11-16 The Children's Hospital Of Philadelphia Adeno-associated viral vectors for targeting deep brain structures
WO2023220386A1 (en) * 2022-05-13 2023-11-16 The Children's Hospital Of Philadelphia Adeno-associated viral vectors for targeting brain microvasculature
US20230398192A1 (en) 2022-05-16 2023-12-14 Genzyme Corporation Methods of treating metachromatic leukodystrophy
WO2024017387A1 (en) * 2022-07-22 2024-01-25 Shanghai Vitalgen Biopharma Co., Ltd. Novel aav capsids for targeting nervous system and uses thereof
KR20240029316A (ko) * 2022-08-26 2024-03-05 경희대학교 산학협력단 활막 표적화 화합물 및 이의 용도
WO2024064673A2 (en) * 2022-09-19 2024-03-28 The Children's Hospital Of Philadelphia Aav evolution at single-cell resolution using split-seq

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040031072A1 (en) * 1999-05-06 2004-02-12 La Rosa Thomas J. Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement
AU2002360291A1 (en) * 2001-12-17 2003-06-30 The Trustees Of The University Of Pennsylvania Adeno-associated virus (aav) serotype 8 sequences
EP3583220A4 (en) * 2017-02-15 2021-07-07 The University of North Carolina at Chapel Hill PROCEDURES AND COMPOSITIONS FOR GENERAL TRANSFER IN THE VASCULAR SYSTEM
US20210324354A1 (en) * 2017-05-12 2021-10-21 The Children's Hospital Of Philadelphia Sulfamidase (sgsh) variants, vectors, compositions and methods and uses for treating mucopolysaccharidosis type iiia (mps iiia)
CR20200165A (es) * 2017-09-20 2020-06-05 4D Molecular Therapeutics Inc Variantes de cápsides de virus adenoasociados y métodos de uso de estas
US20200263199A1 (en) * 2017-09-29 2020-08-20 Voyager Therapeutics, Inc. Rescue of central and peripheral neurological phenotype of friedreich's ataxia by intravenous delivery
US11400168B2 (en) * 2017-12-07 2022-08-02 California Institute Of Technology Methods and systems for noninvasive control of brain cells and related vectors and compositions
EP3793616A1 (en) * 2018-05-15 2021-03-24 Voyager Therapeutics, Inc. Compositions and methods for delivery of aav

Also Published As

Publication number Publication date
EP4061427A4 (en) 2024-01-10
BR112022009864A2 (pt) 2022-08-02
CO2022008507A2 (es) 2022-07-08
JP2023503455A (ja) 2023-01-30
US20230346981A1 (en) 2023-11-02
AU2020388404A1 (en) 2022-06-09
WO2021102234A1 (en) 2021-05-27
CN115023242A (zh) 2022-09-06
EP4061427A1 (en) 2022-09-28
US20240100194A1 (en) 2024-03-28
KR20220116459A (ko) 2022-08-23
IL293140A (en) 2022-07-01
CA3159113A1 (en) 2021-05-27

Similar Documents

Publication Publication Date Title
MX2022006188A (es) Variantes del vector viral adenoasociado.
MX2021006646A (es) Vector viral adenoasociado recombinante para el suministro de genes.
PH12018502645A1 (en) Optimized mini-dystrophin genes and expression cassettes and their use
MX2018006840A (es) Focalizacion de peptidos para dirigir virus adenoasociados.
PH12018502361A1 (en) Gdf15 fusion proteins and uses thereof
CL2022001372A1 (es) Construcciones para terapia génica con microdistrofina y uso de las mismas.
MX2021014552A (es) Vectores viricos y uso de los mismos en terapias celulares adoptivas.
EA201891137A1 (ru) Вирусные векторы, кодирующие рекомбинантные варианты fviii с повышенной экспрессией для генной терапии гемофилии a
EA201990885A1 (ru) Композиции, содержащие короткие пептиды, полученные из pedf, и их применение
MX2017012097A (es) Variantes de virus adenoasociado y métodos de uso de estas.
NZ737757A (en) Peptide oligonucleotide conjugates
SA518390954B1 (ar) لقاحات علاجية لفيروس الورم الحليمي البشري 18
AR086998A1 (es) Coagonistas del receptor de glucagon/glp-1
NZ801728A (en) Atf5 peptide variants and uses thereof
WO2014205317A3 (en) Cyclic peptides as protein targeting agents
MY169703A (en) Antimicrobial fusion compounds and uses thereof
MX2018015629A (es) Sistema de vector viral adeno-asociado traslapado doble para la expresion de abc4a.
MX2020000676A (es) Composiciones y metodos para tratar beta-hemoglobinopatias.
MX2016002937A (es) Vacuna oncologica.
MX2021003420A (es) Peptidos cationicos lipidados amino terciario para la administracion de acido nucleico.
MX2019006515A (es) Composiciones que comprenden peptido wkdeagkplvk.
WO2017053629A3 (en) Light-controlled gene delivery with virus vectors through incorporation of optogenetic proteins and genetic insertion of non-conformationally constrained peptides
MX2021007221A (es) Factor i del complemento y cofactor del factor i del complemento, vectores que realizan codificacion para estos y uso terapeutico.
EA201891138A1 (ru) Вирусные векторы, кодирующие рекомбинантные варианты fviii с повышенной экспрессией для генной терапии гемофилии a
NZ734705A (en) Herbicide resistance protein, and encoding genes and application thereof